Physician profile
Wulf Hirschfield
NPI 1114995537
$1,795.08
in general payments reported to CMS, 2019-2025
23 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $220 · 2021: $532 · 2022: $226 · 2023: $136 · 2024: $354 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $642.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $496.94 | 2021-2025 | |
| Pfizer INC. | $172.92 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $161.71 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $146.32 | 2019-2022 | |
| Lilly USA, LLC | $92.86 | 2021-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $81.30 | 2019-2025 | Ozempic |
| Novartis Pharmaceuticals Corporation | $76.29 | 2022-2023 | |
| Hikma Pharmaceuticals USA | $70.04 | 2020-2021 | |
| Allergan, INC. | $68.77 | 2020 | |
| Janssen Pharmaceuticals, INC | $60.45 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $55.19 | 2019 | |
| Mylan Specialty L.P. | $45.82 | 2023-2024 | Yupelri |
| Amgen INC. | $42.48 | 2021-2024 | Repatha, Evenity, Prolia |
| Xeris Pharmaceuticals, INC. | $38.97 | 2023-2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.80 | 2023-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $32.04 | 2021 | |
| Avanir Pharmaceuticals, INC. | $26.68 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $24.25 | 2024 | Dificid |
| Paratek Pharmaceuticals, INC. | $18.44 | 2025 | Xhance, Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $15.25 | 2025 | |
| Exact Sciences Corporation | $14.33 | 2024 | Cologuard Collection Kit |
| Dexcom, INC. | $12.51 | 2021 | |
| Axsome Therapeutics, INC. | $7.72 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wulf Hirschfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.